To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry

Multiple small-molecule kinase inhibitors with specific molecular targets have recently been developed for the treatment of cancer. This article reports development and validation an ultra-performance liquid chromatography/tandem mass spectrometry (UPLC–MS/MS) method to simultaneously analyse dacomitinib, ceritinib, lorlatinib, nintedanib in human plasma. For chromatographic analyte separation, Acquity UPLC® BEH C18 column 1.7 ?m, 50 mm x 2.1 was used a binary gradient pure water/formic acid/ammonium formate (100:0.1:0.02, v/v/v) methanol/formic acid (100:0.1, v/v). Calibration curves all were 5.00–500 ng/mL. Validation this met requirements Food Drug administration. Additionally, clinical applicability demonstrated by quantification multiple samples from pharmacokinetic study patients lung